InGeNA welcomes our new member Rhythm Biosciences

InGeNA warmly welcomes our new member, Rhythm Biosciences.

Rhythm Biosciences (ASX:RHY) is transforming cancer diagnostics through innovative technologies that predict, detect, characterise, and support early intervention. Their flagship blood-based technology ColoSTAT revolutionises bowel cancer screening, while geneType provides crucial risk assessment across multiple cancer types. They’re creating a comprehensive approach to understanding cancer risk, enabling earlier detection when treatment is most effective. Through scientific innovation and commitment to accessible testing solutions, they’re aiming to reduce healthcare costs and ultimately save lives.

Learn more about Rhythm Biosciences’ vital work at rhythmbio.com.